Related Experiment Video
Updated: Jul 7, 2026

An Assay to Detect Protection of the Retinal Vasculature from Diabetes-Related Death in Mice
Published on: January 12, 2024
The polyol pathway as a mechanism for diabetic retinopathy: attractive, elusive, and resilient
1Schepens Eye Research Institute and Department of Ophthalmology, Harvard Medical School, 20 Staniford Street, Boston, MA 02114, USA. mara.lorenzi@schepens.harvard.edu
Abstract:
The polyol pathway is a two-step metabolic pathway in which glucose is reduced to sorbitol, which is then converted to fructose. It is one of the most attractive candidate mechanisms to explain, at least in part, the cellular toxicity of diabetic hyperglycemia because (i) it becomes active when intracellular glucose concentrations are elevated, (ii) the two enzymes are present in human tissues and organs that are sites of diabetic complications, and (iii) the products of the pathway and the altered balance of cofactors generate the types of cellular stress that occur at the sites of diabetic complications. Inhibition (or ablation) of aldose reductase, the first and rate-limiting enzyme in the pathway, reproducibly prevents diabetic retinopathy in diabetic rodent models, but the results of a major clinical trial have been disappointing. Since then, it has become evident that truly informative indicators of polyol pathway activity and/or inhibition are elusive, but are likely to be other than sorbitol levels if meant to predict accurately tissue consequences. The spectrum of abnormalities known to occur in human diabetic retinopathy has enlarged to include glial and neuronal abnormalities, which in experimental animals are mediated by the polyol pathway. The endothelial cells of human retinal vessels have been noted to have aldose reductase. Specific polymorphisms in the promoter region of the aldose reductase gene have been found associated with susceptibility or progression of diabetic retinopathy. This new knowledge has rekindled interest in a possible role of the polyol pathway in diabetic retinopathy and in methodological investigation that may prepare new clinical trials. Only new drugs that inhibit aldose reductase with higher efficacy and safety than older drugs will make possible to learn if the resilience of the polyol pathway means that it has a role in human diabetic retinopathy that should not have gone undiscovered.
Insights
The polyol pathway, linked to diabetic complications, shows promise for treating diabetic retinopathy. New aldose reductase inhibitors may reveal its true role in the disease.
Area of Science:
- Biochemistry and Metabolism
- Endocrinology and Diabetes
- Ophthalmology
Background:
- The polyol pathway, converting glucose to sorbitol and then fructose, is implicated in diabetic hyperglycemia's cellular toxicity.
- Its enzymes are present in tissues affected by diabetic complications, and pathway products induce cellular stress.
- Aldose reductase, the rate-limiting enzyme, inhibition prevents retinopathy in rodent models, but clinical trials yielded disappointing results.
Purpose of the Study:
- To re-evaluate the polyol pathway's role in diabetic retinopathy given new insights.
- To explore the potential of novel aldose reductase inhibitors for future clinical trials.
Main Methods:
- Review of existing literature and experimental findings on the polyol pathway and diabetic retinopathy.
- Analysis of recent discoveries including glial/neuronal abnormalities and aldose reductase in retinal endothelial cells.
- Consideration of genetic polymorphisms in the aldose reductase gene associated with retinopathy susceptibility.
Main Results:
- Previous clinical trial results for aldose reductase inhibition were disappointing, suggesting limitations in current indicators of pathway activity.
- New evidence points to glial and neuronal involvement in diabetic retinopathy mediated by the polyol pathway.
- Aldose reductase gene polymorphisms correlate with diabetic retinopathy risk and progression.
Conclusions:
- Despite past setbacks, renewed interest in the polyol pathway's role in diabetic retinopathy is warranted.
- Development of highly effective and safe aldose reductase inhibitors is crucial for future therapeutic exploration.
- Further research is needed to determine if the polyol pathway's resilience indicates an undiscovered role in human diabetic retinopathy.
Related Concept Videos
Diabetic Retinopathy
Diabetic Neuropathy
Type I Diabetes II: Pathophysiology
Type II Diabetes II: Pathophysiology
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Diabetic Nephropathy

